Fiji vs Latvia: Cause of death, by non-communicable diseases, ages 5-14, male
Fiji
36.6%
in 2021
Latvia
35.8%
in 2021
Fiji rank
85th
Latvia rank
88th
Cause of death, by non-communicable diseases, ages 5-14, male over time
- Fiji
- Latvia
How they compare
Fiji currently reports 36.6% against 35.8% in Latvia, a difference of 0.8%.
The two have swapped places 2 times across 6 shared years of data; in 2000 it was Fiji ahead.
Fiji ranks 85th and Latvia ranks 88th of 185 countries.
Across the 3 decades both report, Fiji averaged higher in 2 and Latvia in 1.
Head to head by decade
| Decade | Fiji | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 36.3% | 33.4% | 2.8% | Fiji |
| 2010s | 39.1% | 49.6% | 10.4% | Latvia |
| 2020s | 39.1% | 35.1% | 4.0% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 5-14, male, Fiji or Latvia?
- Fiji, at 36.6% against 35.8% in Latvia as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 5-14, male between Fiji and Latvia?
- 0.8%, with Fiji ahead.
- How many years of comparable data are there for Fiji and Latvia?
- 6 years are reported by both, from 2000 to 2021.
- How do Fiji and Latvia rank globally for cause of death, by non-communicable diseases, ages 5-14, male?
- Fiji ranks 85th and Latvia ranks 88th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 5-14, male (% of total male deaths ages 5-14). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of male deaths ages 5-14 due to non-communicable diseases divided by number of all male deaths ages 5-14, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.